脂肪性肝疾患(Fatty Liver Disease)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fatty Liver Disease Overview 10
Therapeutics Development 11
Pipeline Products for Fatty Liver Disease – Overview 11
Pipeline Products for Fatty Liver Disease – Comparative Analysis 12
Fatty Liver Disease – Therapeutics under Development by Companies 13
Fatty Liver Disease – Therapeutics under Investigation by Universities/Institutes 16
Fatty Liver Disease – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Fatty Liver Disease – Products under Development by Companies 21
Fatty Liver Disease – Products under Investigation by Universities/Institutes 23
Fatty Liver Disease – Companies Involved in Therapeutics Development 24
ACROVIS biostructures GmbH 24
ChemoCentryx, Inc. 25
Conatus Pharmaceuticals Inc. 26
Daewoong Pharmaceutical Co., Ltd. 27
Dr. Falk Pharma GmbH 28
DURECT Corporation 29
Galmed International Ltd. 30
Generon (Shanghai) Corporation Ltd. 31
Genovate Biotechnology Co., LTD. 32
Gilead Sciences, Inc. 33
Huons Co., Ltd. 34
Kyorin Pharmaceutical Co., Ltd. 35
Metabolic Solutions Development Company, LLC 36
Novartis AG 37
Protalix BioTherapeutics, Inc. 38
Raptor Pharmaceuticals Corp. 39
TCM Biotech International Corp 40
Tobira Therapeutics, Inc. 41
Verva Pharmaceuticals Limited 42
Zafgen Inc. 43
Fatty Liver Disease – Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 51
Drug Profiles 53
ACR-488 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Aramchol – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CCX-872 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
cenicriviroc mesylate – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CSN-501 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
cysteamine DR – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DV-928 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DWP-10292 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
emricasan – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
etanercept biosimilar – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
F-652 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
HU-002 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MAT-8800 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MB-12066 – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
methazolamide – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MN-002 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MSDC-0602 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
norursodeoxycholic acid – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
oltipraz – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
PCBB-7 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pradigastat sodium – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Px-102 – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Px-103 – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Px-104 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Recombinant Protein for Atherosclerosis and Hepatic Steatosis – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecules to Activate AMPK for Fatty Liver Disease – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SR-9238 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TCM-606F – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
VVP-100-X – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ZGN-839 – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Fatty Liver Disease – Recent Pipeline Updates 95
Fatty Liver Disease – Dormant Projects 112
Fatty Liver Disease – Product Development Milestones 114
Featured News & Press Releases 114
Jan 12, 2015: Researchers uncover more clues to how drug reverses obesity, diabetes, fatty liver disease 114
Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 115
Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 116
Mar 03, 2014: Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial 116
Dec 19, 2012: Scripps Florida Scientists Develop New Compound that Reverses Fatty Liver Disease 117
Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 118
Oct 06, 2011: Metabolic Solutions Development Company Receives $1.1m NIH Grant To Further Investigate MSDC-0602 For Treatment Of Fatty Liver Disease 119
Oct 14, 2010: Galmed Initiates Phase II Clinical Trial Of Aramchol For Treatment Of Fatty Liver Disease 119
Sep 21, 2008: Galmed Medical Research Initiates Its Phase I study Of Aramchol, Its Drug Candidate For Fatty Liver Disease 120
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123